MMOVE project: Make MRD valued & endorsed

A collaboration between the BHS MM working group & Janssen-Cilag NV

                                                                                                    

ABOUT MRD Testing

MRD (minimal residual disease) testing is a more sensitive measure compared with traditional definitions of clinical response which helps to detect residual tumor cells in the bone marrow and to better discriminate patients at risk for relapsing accordingly. 


MMOVE PROJECT'S GOAL

The goal of treatment in multiple myeloma is achieving deep and durable responses, but MRD is currently not widely measured in Belgium due practical & financial limitations.

MMOVE project aims to make MRD measurement available for multiple myeloma patients in Belgium: 


MMOVE PROJECT WORKFLOW

To achieve this goal, the BHS Multiple Myeloma-workgroup initiated a cooperation with Janssen-Cilag NV:



MRD Workflow - UZ Brussel

MRD Workflow - UZ Leuven

MRD Workflow - CHU Li├Ęge

     Jessa Ziekenhuis Hasselt

           CHR de Namur